Nephros Stock EBITDA
| NEPH Stock | USD 1.61 0.02 1.23% |
Nephros fundamentals help investors to digest information that contributes to Nephros' financial success or failures. It also enables traders to predict the movement of Nephros Stock. The fundamental analysis module provides a way to measure Nephros' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nephros stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 193 K | 202.7 K |
Nephros | EBITDA |
Nephros Company EBITDA Analysis
Nephros' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Nephros EBITDA | 193 K |
Most of Nephros' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nephros is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Nephros EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Nephros is extremely important. It helps to project a fair market value of Nephros Stock properly, considering its historical fundamentals such as EBITDA. Since Nephros' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nephros' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nephros' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Nephros Ebitda
Ebitda |
|
According to the company disclosure, Nephros reported earnings before interest,tax, depreciation and amortization of 193 K. This is 99.98% lower than that of the Household Durables sector and 99.96% lower than that of the Consumer Discretionary industry. The ebitda for all United States stocks is 100.0% higher than that of the company.
Nephros EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nephros' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nephros could also be used in its relative valuation, which is a method of valuing Nephros by comparing valuation metrics of similar companies.Nephros is currently under evaluation in ebitda category among its peers.
Nephros Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nephros from analyzing Nephros' financial statements. These drivers represent accounts that assess Nephros' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nephros' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 75.0M | 77.9M | 11.9M | 35.9M | 15.5M | 19.7M | |
| Enterprise Value | 73.4M | 71.8M | 9.4M | 33.5M | 30.1M | 18.9M |
Nephros Institutional Holders
Institutional Holdings refers to the ownership stake in Nephros that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nephros' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nephros' value.| Shares | Citadel Advisors Llc | 2024-12-31 | 14.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-12-31 | 13.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 5.4 K | Tower Research Capital Llc | 2024-12-31 | 2.6 K | Bank Of America Corp | 2024-12-31 | 76.0 | Jpmorgan Chase & Co | 2024-12-31 | 15.0 | Royal Bank Of Canada | 2024-12-31 | 2.0 | Granite Investment Partners, Llc | 2024-09-30 | 0.0 | Dimensional Fund Advisors, Inc. | 2024-12-31 | 0.0 | Wexford Capital Lp | 2024-12-31 | 3.6 M | Topline Capital Management Llc | 2024-12-31 | 419.9 K |
Nephros Fundamentals
| Return On Equity | 0.0087 | ||||
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 14.84 M | ||||
| Shares Outstanding | 10.54 M | ||||
| Shares Owned By Insiders | 12.86 % | ||||
| Shares Owned By Institutions | 44.69 % | ||||
| Number Of Shares Shorted | 9.57 K | ||||
| Price To Earning | (4.51) X | ||||
| Price To Book | 2.00 X | ||||
| Price To Sales | 1.21 X | ||||
| Revenue | 14.16 M | ||||
| Gross Profit | 8.72 M | ||||
| EBITDA | 193 K | ||||
| Net Income | (1.57 M) | ||||
| Cash And Equivalents | 4.18 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 1.84 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 5.27 X | ||||
| Book Value Per Share | 0.81 X | ||||
| Cash Flow From Operations | 827 K | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | 0.01 X | ||||
| Target Price | 4.75 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 17.19 M | ||||
| Total Asset | 11.86 M | ||||
| Retained Earnings | (144.41 M) | ||||
| Working Capital | 6.29 M | ||||
| Current Asset | 1.53 M | ||||
| Current Liabilities | 684 K | ||||
| Net Asset | 11.86 M |
About Nephros Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nephros's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nephros using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nephros based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Nephros offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nephros' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nephros Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nephros Stock:Check out Nephros Piotroski F Score and Nephros Altman Z Score analysis. For more detail on how to invest in Nephros Stock please use our How to Invest in Nephros guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Household Appliances space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth 0.189 | Return On Assets | Return On Equity |
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nephros is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.